Wiki-Pi

Search Results for: Alzheimer

3183 interactions found:

Sort by: Relevance Number of Pathways Number of Drugs Number of Diseases
Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
BACE1 and APP beta-site APP-cleaving enzyme 1 amyloid beta (A4) precursor protein
  • Signaling by GPCR
  • Platelet degranulation
  • Metabolic disorders of biological oxidation enzymes
  • RIP-mediated NFkB activation via ZBP1
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • Amyloids
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Peptide ligand-binding receptors
  • Toll Like Receptor 5 (TLR5) Cascade
  • The NLRP3 inflammasome
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Response to elevated platelet cytosolic Ca2+
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • G alpha (i) signalling events
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Platelet activation, signaling and aggregation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • G alpha (q) signalling events
  • Class A/1 (Rhodopsin-like receptors)
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • ZBP1(DAI) mediated induction of type I IFNs
  • ECM proteoglycans
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Advanced glycosylation endproduct receptor signaling
  • Innate Immune System
  • Inflammasomes
  • Cytosolic sensors of pathogen-associated DNA
  • MyD88-independent cascade
  • GPCR ligand binding
  • Toll-Like Receptors Cascades
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • TRAF6 mediated NF-kB activation
  • MMI-175
  • N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide
  • N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE
  • N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide
  • 4-(4-FLUOROBENZYL)PIPERIDINE
  • N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide
  • 6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE
  • 6-[2-(3\'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE
  • N~3~-BENZYLPYRIDINE-2,3-DIAMINE
  • N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE
  • N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE
  • 4-(2-aminoethyl)-2-cyclohexylphenol
  • 4-(2-aminoethyl)-2-ethylphenol
  • 4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine
  • (6R)-2-amino-6-[2-(3\'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one
  • 2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one
  • (2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol
  • N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
  • N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide
  • (2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide
  • (2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide
  • N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide
  • (6S)-2-amino-6-(3\'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one
  • N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE
  • N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE
  • 3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE
PDE4B and DISC1 phosphodiesterase 4B, cAMP-specific disrupted in schizophrenia 1
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Opioid Signalling
  • DARPP-32 events
  • Adenosine monophosphate
  • Caffeine
  • Theophylline
  • Dyphylline
  • Pentoxifylline
  • Enprofylline
  • Ketotifen
  • Iloprost
  • Papaverine
  • Theobromine
  • Amrinone
  • (R)-Mesopram
  • Roflumilast
  • Piclamilast
  • 4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]-2-Pyrrolidinone
  • 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • Filaminast
  • 8-Bromo-Adenosine-5\'-Monophosphate
  • (S)-Rolipram
  • 1-(2-Chlorophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • Cis-4-Cyano-4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]Cyclohexanecarboxylic Acid
  • (R)-Rolipram
  • S,S-(2-Hydroxyethyl)Thiocysteine
  • Ibudilast
  • 1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
  • 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
BACE1 and PSEN1 beta-site APP-cleaving enzyme 1 presenilin 1
  • Degradation of the extracellular matrix
  • MMI-175
  • N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide
  • N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE
  • N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide
  • 4-(4-FLUOROBENZYL)PIPERIDINE
  • N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide
  • 6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE
  • 6-[2-(3\'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE
  • N~3~-BENZYLPYRIDINE-2,3-DIAMINE
  • N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE
  • N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE
  • 4-(2-aminoethyl)-2-cyclohexylphenol
  • 4-(2-aminoethyl)-2-ethylphenol
  • 4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine
  • (6R)-2-amino-6-[2-(3\'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one
  • 2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one
  • (2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol
  • N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
  • N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide
  • (2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide
  • (2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide
  • N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide
  • (6S)-2-amino-6-(3\'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one
  • N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE
  • N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE
  • 3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE
NOS1 and CAMK4 nitric oxide synthase 1 (neuronal) calcium/calmodulin-dependent protein kinase IV
  • Platelet homeostasis
  • Phagosomal maturation (early endosomal stage)
  • Latent infection of Homo sapiens with Mycobacterium tuberculosis
  • Nitric oxide stimulates guanylate cyclase
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Organelle biogenesis and maintenance
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • DAG and IP3 signaling
  • CaM pathway
  • DAP12 signaling
  • Downstream signaling of activated FGFR
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Post NMDA receptor activation events
  • Innate Immune System
  • Signaling by PDGF
  • Calmodulin induced events
  • Signalling by NGF
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • PLC beta mediated events
  • Opioid Signalling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • EGFR interacts with phospholipase C-gamma
  • Mitochondrial biogenesis
  • Signaling by ERBB2
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by EGFR
  • Activation of CaMK IV
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • PLC-gamma1 signalling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Transmission across Chemical Synapses
  • L-Citrulline
  • L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide
  • Formic Acid
  • 3-Bromo-7-Nitroindazole
  • N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N\'-Nitroguanidine
  • N-(3-(Aminomethyl)Benzyl)Acetamidine
  • L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide
  • N-Isopropyl-N\'-Hydroxyguanidine
  • N-Omega-Propyl-L-Arginine
  • (6r,1\'r,2\'s)-5,6,7,8 Tetrahydrobiopterin
  • N-Butyl-N\'-Hydroxyguanidine
  • Alpha-D-Mannose
  • S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
  • Heme
  • N-Omega-Hydroxy-L-Arginine
  • Flavin-Adenine Dinucleotide
  • Riboflavin Monophosphate
  • N-(4-(2-((3-Chlorophenylmethyl)Amino)Ethyl)Phenyl)-2-Thiophecarboxamidine
  • 2\'-Monophosphoadenosine 5\'-Diphosphoribose
  • S-Ethyl-N-Phenyl-Isothiourea
  • N5-(1-Imino-3-Butenyl)-L-Ornithine
  • 5-N-Allyl-Arginine
  • Nitroarginine
  • N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N\'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
  • N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N\'-(3-chlorobenzyl)ethane-1,2-diamine
CSNK2A1 and APOE casein kinase 2, alpha 1 polypeptide apolipoprotein E
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Lipoprotein metabolism
  • Metabolism of lipids and lipoproteins
  • Chylomicron-mediated lipid transport
  • Lipid digestion, mobilization, and transport
  • Diseases associated with visual transduction
  • HDL-mediated lipid transport
  • Visual phototransduction
  • Scavenging by Class A Receptors
  • Retinoid metabolism and transport
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
  • Human Serum Albumin
  • Serum albumin iodonated
CSNK2A1 and APP casein kinase 2, alpha 1 polypeptide amyloid beta (A4) precursor protein
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Signaling by GPCR
  • Platelet degranulation
  • Metabolic disorders of biological oxidation enzymes
  • RIP-mediated NFkB activation via ZBP1
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • Amyloids
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Peptide ligand-binding receptors
  • Toll Like Receptor 5 (TLR5) Cascade
  • The NLRP3 inflammasome
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Response to elevated platelet cytosolic Ca2+
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • G alpha (i) signalling events
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • G alpha (q) signalling events
  • GPCR downstream signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Platelet activation, signaling and aggregation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • G alpha (q) signalling events
  • Class A/1 (Rhodopsin-like receptors)
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • ZBP1(DAI) mediated induction of type I IFNs
  • ECM proteoglycans
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Advanced glycosylation endproduct receptor signaling
  • Innate Immune System
  • Inflammasomes
  • Cytosolic sensors of pathogen-associated DNA
  • MyD88-independent cascade
  • GPCR ligand binding
  • Toll-Like Receptors Cascades
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • TRAF6 mediated NF-kB activation
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and SLC4A1AP casein kinase 2, alpha 1 polypeptide solute carrier family 4 (anion exchanger), member 1, adaptor protein
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A1 and PSEN2 casein kinase 2, alpha 1 polypeptide presenilin 2
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Axon guidance
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • EPH-ephrin mediated repulsion of cells
  • Signaling by NOTCH1
  • EPH-Ephrin signaling
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Signaling by NOTCH4
  • Regulated proteolysis of p75NTR
  • Signalling by NGF
  • Cell death signalling via NRAGE, NRIF and NADE
  • Signaling by NOTCH
  • p75 NTR receptor-mediated signalling
  • Signaling by ERBB4
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Nuclear signaling by ERBB4
  • NRIF signals cell death from the nucleus
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH3
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
MMP3 and PLG matrix metallopeptidase 3 (stromelysin 1, progelatinase) plasminogen
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Signaling by PDGF
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Activation of Matrix Metalloproteinases
  • Dissolution of Fibrin Clot
  • Platelet degranulation
  • Degradation of the extracellular matrix
  • Response to elevated platelet cytosolic Ca2+
  • Platelet activation, signaling and aggregation
  • Orphan transporters
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
  • Alteplase
  • Urokinase
  • Reteplase
  • Anistreplase
  • Tenecteplase
  • Streptokinase
  • Tranexamic Acid
  • Aminocaproic Acid
  • Bicine
  • Aprotinin
MMP3 and SERPINE1 matrix metallopeptidase 3 (stromelysin 1, progelatinase) serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Loss of Function of TGFBR2 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Platelet degranulation
  • Dissolution of Fibrin Clot
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Generic Transcription Pathway
  • Response to elevated platelet cytosolic Ca2+
  • ECM proteoglycans
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • Platelet activation, signaling and aggregation
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • SMAD4 MH2 Domain Mutants in Cancer
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
  • Alteplase
  • Urokinase
  • Reteplase
  • Anistreplase
  • Tenecteplase
  • Drotrecogin alfa
  • Troglitazone
MMP3 and CCL2 matrix metallopeptidase 3 (stromelysin 1, progelatinase) chemokine (C-C motif) ligand 2
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • Class A/1 (Rhodopsin-like receptors)
  • ATF4 activates genes
  • GPCR ligand binding
  • Metabolic disorders of biological oxidation enzymes
  • Peptide ligand-binding receptors
  • Chemokine receptors bind chemokines
  • PERK regulates gene expression
  • Unfolded Protein Response (UPR)
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
  • Mimosine
  • Danazol
MMP3 and IGFBP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) insulin-like growth factor binding protein 3
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
  • Mecasermin
MMP3 and ACAN matrix metallopeptidase 3 (stromelysin 1, progelatinase) aggrecan
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and HAPLN1 matrix metallopeptidase 3 (stromelysin 1, progelatinase) hyaluronan and proteoglycan link protein 1
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • ECM proteoglycans
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and DCN matrix metallopeptidase 3 (stromelysin 1, progelatinase) decorin
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • MPS IIIB - Sanfilippo syndrome B
  • Diseases of glycosylation
  • Heparan sulfate/heparin (HS-GAG) metabolism
  • Defective B4GALT7 causes EDS, progeroid type
  • MPS I - Hurler syndrome
  • MPS IX - Natowicz syndrome
  • Chondroitin sulfate/dermatan sulfate metabolism
  • CS/DS degradation
  • Defective SLC26A2 causes chondrodysplasias
  • Glycosaminoglycan metabolism
  • Degradation of the extracellular matrix
  • Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
  • Defective CHST14 causes EDS, musculocontractural type
  • Defective PAPSS2 causes SEMD-PA
  • MPS IIIA - Sanfilippo syndrome A
  • Myoclonic epilepsy of Lafora
  • ECM proteoglycans
  • Defective CHST6 causes MCDC1
  • Glycogen storage diseases
  • MPS IIID - Sanfilippo syndrome D
  • A tetrasaccharide linker sequence is required for GAG synthesis
  • Chondroitin sulfate biosynthesis
  • MPS IIIC - Sanfilippo syndrome C
  • Diseases associated with glycosaminoglycan metabolism
  • Mucopolysaccharidoses
  • Defective EXT2 causes exostoses 2
  • MPS II - Hunter syndrome
  • Defective B3GAT3 causes JDSSDHD
  • Defective CHST3 causes SEDCJD
  • Defective EXT1 causes exostoses 1, TRPS2 and CHDS
  • MPS IV - Morquio syndrome A
  • Dermatan sulfate biosynthesis
  • MPS IV - Morquio syndrome B
  • Defective CHSY1 causes TPBS
  • MPS VII - Sly syndrome
  • Metabolism of carbohydrates
  • MPS VI - Maroteaux-Lamy syndrome
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and MEOX2 matrix metallopeptidase 3 (stromelysin 1, progelatinase) mesenchyme homeobox 2
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and TIMP1 matrix metallopeptidase 3 (stromelysin 1, progelatinase) TIMP metallopeptidase inhibitor 1
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Response to elevated platelet cytosolic Ca2+
  • Activation of Matrix Metalloproteinases
  • Platelet degranulation
  • Platelet activation, signaling and aggregation
  • Degradation of the extracellular matrix
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and CCL8 matrix metallopeptidase 3 (stromelysin 1, progelatinase) chemokine (C-C motif) ligand 8
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and TIMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) TIMP metallopeptidase inhibitor 3
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
MMP3 and SPOCK1 matrix metallopeptidase 3 (stromelysin 1, progelatinase) sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1
  • Signaling by GPCR
  • EGFR Transactivation by Gastrin
  • Collagen formation
  • Collagen degradation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Activation of Matrix Metalloproteinases
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Marimastat
  • N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
  • 3-Methylpyridine
  • A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
  • N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
  • (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
  • 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
  • Hydroxyaminovaline
  • 1-Methyloxy-4-Sulfone-Benzene
  • 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
  • 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
  • N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
  • R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
  • [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
  • [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
  • 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
  • N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
  • 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
  • N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
  • N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
  • 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER

Page 2 out of 160 pages